Phenotypes associated with this allele

• Allele Symbol: Col1a1^{tm1(tetO-Yod1*)Hpl}
• Allele Name: targeted mutation 1, Hidde Ploegh
• Allele ID: MGI:5478606
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Col1a1^tm1(tetO-Yod1*)Hpl/Col1a1^tm1(tetO-Yod1*)Hpl Gt(ROSA)26Sor^tm1(rtTA*M2)Jae/Gt(ROSA)26Sor^tm1(rtTA*M2)Jae Tap1^tm1Arp/Tap1^tm1Arp	involves: 129S2/SvPas * 129S4/SvJae * C57BL/6	MGI:5478623
cx2	Col1a1^tm1(tetO-Yod1*)Hpl/Col1a1^tm1(tetO-Yod1*)Hpl Gt(ROSA)26Sor^tm1(rtTA*M2)Jae/Gt(ROSA)26Sor^tm1(rtTA*M2)Jae	involves: 129S4/SvJae * C57BL/6	MGI:5478622

Genotype
MGI:5478623

cx1

• Allelic Composition: Col1a1^{tm1(tetO-Yod1*)Hpl}/Col1a1^{tm1(tetO-Yod1*)Hpl}; Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}/Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}; Tap1^tm1Arp/Tap1^tm1Arp
• Genetic Background: involves: 129S2/SvPas * 129S4/SvJae * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

abnormal professional antigen presenting cell physiology ( J:194608 )

• APCs from doxycycline-treated mice exhibit enhanced antigen cross-presentation compared with control cells

Genotype
MGI:5478622

cx2

• Allelic Composition: Col1a1^{tm1(tetO-Yod1*)Hpl}/Col1a1^{tm1(tetO-Yod1*)Hpl}; Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}/Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}
• Genetic Background: involves: 129S4/SvJae * C57BL/6

immune system

immune system phenotype ( J:194608 )

N • doxycycline-treated mice exhibit normal T cell distribution in lymphoid organs

abnormal CD8-positive, alpha-beta T cell physiology ( J:194608 )

• CD8+ T cells from doxycycline-treated mice exhibit enhanced response to immunization with viral infection and improved viral growth control compared with control cells

abnormal professional antigen presenting cell physiology ( J:194608 )

• following exposure to ovalbumin, antigen presenting cells (APCs) from doxycycline-treated mice exhibit enhanced antigen cross-production with increased induction of proliferation and IL2 production in OT-I cells compared with control cells

• following infection with MHV-68 and irradiation, bone marrow derived dendritic cells from doxycycline-treated mice prime more effective CD8+ T cell response compared with control cells

• APCs from doxycycline-treated mice exhibit prolonged antigen retention compared with control cells

• cross-presentation in doxycycline-treated mice requires acidification and is insensitive to brefeldin compared to in control cells

• however, antigen presentation in doxycycline-treated mice is normal

hematopoietic system

abnormal CD8-positive, alpha-beta T cell physiology ( J:194608 )

• CD8+ T cells from doxycycline-treated mice exhibit enhanced response to immunization with viral infection and improved viral growth control compared with control cells